Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open Label, Single Dose, Parallel Group Study To Evaluate The Plasma Pharmacokinetics Of Glasdegib (Pf-04449913) In Healthy Subjects With Normal Hepatic Function And In Subjects With Impaired Hepatic Function

Next Previous
Trial Profile

A Phase 1, Open Label, Single Dose, Parallel Group Study To Evaluate The Plasma Pharmacokinetics Of Glasdegib (Pf-04449913) In Healthy Subjects With Normal Hepatic Function And In Subjects With Impaired Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glasdegib (Primary)
  • Indications Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting
  • 21 Mar 2020 Results assessing Glasdegib plasma exposure participants with moderate and severe hepatic impairment presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 01 May 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top